Frontlight ResearchEarly access
CompletedNo phase
Real World Evaluation of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With ITP
Key facts
- Who runs it
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Where
- Italy21 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 95 people enrolled
- Started
- 5 May 2023
- Ended
- 31 May 2024
- Type of study
- Observational
- Treatments tested
- Fostamatinib
- Record updated
- 30 April 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Patients with chronic ITP who are refractory to other treatments and who received Fostamatinib according to standard clinical practice between October 1st, 2021 and April 1st, 2023
- Age greater or equal to 18 years at the treatment start
- Signed written informed consent document (if feasible) according to ICH/EU/GCP and national local laws
Who cannot take part
- Contraindications or hypersensitivity to Fostamatinib, its active substance or any of its excipients
- Patients participating in an interventional clinical trial at the time of enrollment
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a retrospective and prospective multicenter observational study with the aim to evaluate the real-life use of Fostamatinib in adult patients with chronic ITP, refractory to other treatments.
The group in the trial
- Study group
All patients being observed during the study duration.
Treatment: Fostamatinib
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Real World Evaluation Among Italian Centers of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With Immune Thrombocytopenia (ITP)
- Record updated
- 30 April 2025